Starting from Scratch in Timor-Leste : Establishing a Pharmaceutical and Medical Supplies System in a Post-Conflict Context
Author(s)
Huff-Rousselle, MaggieKeywords
PHARMACEUTICAL PROCUREMENTSALES
HOSPITAL
JOB TRAINING
AGED
FAMILY HEALTH INTERNATIONAL
FERTILITY
MEDICAL SUPPLIES
QUININE
RESOURCE CONSTRAINTS
TECHNICAL ASSISTANCE
INFORMATION SYSTEMS
HEALTH INFORMATION
REGULATORY AUTHORITY
HEALTH SPECIALIST
DELIVERY SYSTEMS
INFANT MORTALITY RATES
NURSES
MIGRATION
LACK OF KNOWLEDGE
IMMUNIZATION
NATIONALS
PHARMACIES
LITERACY
CASH FLOW
ESSENTIAL DRUGS CONCEPT
INFORMATION SYSTEM
NATIONAL DRUG
CHILDHOOD DISEASES
ABUSE
QUALITY OF SERVICES
DEATHS
HEALTH SYSTEMS
STOCKS
STANDARD TREATMENT GUIDELINES
PHARMACEUTICAL
HEALTH SERVICES
VIOLENCE
CONSUMER
PUBLIC HEALTH
HUMAN RESOURCES
HUMAN DEVELOPMENT
DEVELOPMENT STRATEGIES
UNDER-FIVE MORTALITY
SAVINGS
PHARMACEUTICAL SUPPLY MANAGEMENT
MALARIA
PREGNANT WOMEN
PATIENT
PHARMACISTS
CENTRAL MEDICAL STORES
RAPID GROWTH
PHARMACEUTICAL PRODUCTS
WORLD HEALTH ORGANIZATION
ACCOUNTING
SALE
COLD CHAIN
HEALTH ADMINISTRATION
SHORT SUPPLY
PROJECT IMPLEMENTATION
CUSTOMS CLEARANCE
HEALTH PLANNING
POLIO
CORRUPTION
TRADITIONAL HEALERS
HEALTH CARE SYSTEM
AMOUNT OF MONEY
BRAIN DRAIN
SERVICE DELIVERY
PHARMACEUTICALS
TENDERING
PHARMACEUTICAL POLICY
HEALTH SECTOR REFORM
INFANT
ACCESS TO FUNDS
CREDIT HISTORY
UNFPA
NUTRITION
PERSONAL COMMUNICATION
POPULATION ACTIVITIES
HEALTH SERVICE DELIVERY
INFLATION
PATIENTS
MORTALITY
HEALTH WORKERS
HEALTH INFORMATION SYSTEM
SKILLED STAFF
GMP
INFANT MORTALITY
MEDICINES
CAPSULES
PEACEKEEPING
PHARMACEUTICAL INDUSTRY
HEALTH SYSTEM
SOCIAL SCIENCE
COMMODITIES
TECHNICAL INFORMATION
REHABILITATION
STAKEHOLDER
MEDICAL] STORES
DOCTORS
FOCUS GROUP DISCUSSIONS
COMPLICATIONS
LABOR MARKET
TABLETS
TETANUS
PHYSICIANS
FINANCIAL SYSTEMS
TUBERCULOSIS
PHARMACEUTICAL SECTOR
MINISTRY OF HEALTH
PHYSICIAN
DEBTS
QUALITY CONTROL
FORCED MIGRATION
SOCIAL SECTORS
LIVE BIRTHS
PRIMARY HEALTH CARE FACILITIES
SUPPLY SYSTEMS
CHARTS
PROGRESS
FINANCIAL PLAN
STAKEHOLDERS
LACK OF AWARENESS
FINANCIAL CONSTRAINT
REFUGEES
ECONOMIC DEVELOPMENT
EQUITABLE ACCESS
PHARMACOLOGY
LOCAL POPULATION
DEBT
RATIONAL DRUG USE
INTERNATIONAL ASSISTANCE
OPERATING COSTS
BALANCE SHEET
CREDITS
EMERGENCIES
CLINICS
THERAPEUTICS
INFECTIOUS DISEASES
HEALTH-SECTOR
COMMODITY
NEONATAL HEALTH
TRANSPORTATION
GOOD MANUFACTURING PRACTICES
DEVELOPMENT PLANNING
CONSUMERS
FINANCIAL PLANNING
FINANCIAL RESOURCES
FAMILY PLANNING
BUSINESS PLAN
HEALTH ECONOMICS
PHARMACY
HEALTH CARE
CHILDREN PER WOMAN
VACCINES
DIPHTHERIA
RESPONSIBILITIES
HEALTH FACILITIES
INTEGRATION
HOSPITALS
CATHETERS
DRUG DONATIONS
PUBLIC HEALTH CARE
HEALTH POLICY
HEALTH PROFESSIONALS
QUALITY ASSURANCE
HEALTH SERVICE
QUANTITATIVE DATA
PHARMACY ASSISTANTS
ESSENTIAL MEDICINES
COMMITTEE ON POPULATION
PHARMACEUTICAL SUPPLY
PURCHASING
REPRODUCTIVE HEALTH
ILLNESS
SANITATION
DEVELOPING COUNTRIES
ESSENTIAL DRUGS
WORKERS
LAWS
HEALTH INFRASTRUCTURE
FAMILY HEALTH
FERTILITY RATE
MEASLES
NATIONAL RESEARCH COUNCIL
TRAINING INTERVENTIONS
BANK ACCOUNT
SALARIES
COUNTERFEIT DRUGS
WASTE
MEDICINE
PROCUREMENT
GRAPHICS
PRIMARY HEALTH CARE
DONATIONS
DISASTERS
HEALTH SECTOR
SENIOR
MEDICAL EQUIPMENT
GROUP DISCUSSIONS
NRC
POLICY FRAMEWORK
COMPETITIVE BIDDING
SMALL COUNTRIES
WORKING CAPITAL
Full record
Show full item recordOnline Access
http://hdl.handle.net/10986/13760Abstract
This case study analyses the challenges of establishing a pharmaceutical and medical supplies system in a Timor-Leste post-conflict context. In the aftermath of its separation from Indonesia, the Timor-Leste health infrastructure was in total disarray, with more than a third of health facilities destroyed, and those remaining severely damaged. The crisis in human resources was severe, as more than 80 percent of qualified public-sector staff had returned to Indonesia. The resultant heavy dependence on expatriates was complicated by language incompatibility, and nationals were not well integrated into planning and implementation processes, as an entire public sector infrastructure was being established de nouveau. Despite the fledgling status of the public sector, a sophisticated organizational framework was envisioned for the establishment of the health sector supply system: an autonomous agency that would be a non-profit wholesaler or revolving drug fund and a public sector monopoly. The case study reviews the development of the policy and legal framework for the pharmaceutical sector, and the key phases of the commodity supply system, including: product selection through an essential drugs list; procurement hampered by use of procedures that were not appropriate for purchasing drugs for an entire country; the establishment of a centralized warehousing and distribution system; projected financing of the supply system through development of a business plan for the autonomous agency. In its exploration of the transition from post-conflict situation to health system development, the case study identifies lessons that are broadly applicable to foreign aid and external assistance in other contexts, including the tendency to 'poly-prescribe' overly ambitious and overly sophisticated solutions not pragmatically grounded in the current realities of public sector institutional and human resource constraints and capabilities.Date
2013-06-05Identifier
oai:openknowledge.worldbank.org:10986/13760http://hdl.handle.net/10986/13760
Copyright/License
http://creativecommons.org/licenses/by/3.0/Collections
Related items
Showing items related by title, author, creator and subject.
-
Improving Transparency in Pharmaceutical Systems : Strengthening Critical Decision Points Against CorruptionMacaya, Roman; Cohen, Jillian Clare; Cercone, James A. (World Bank, Washington, DC, 2002-10)This study presents a diagnostic framework and methodology to evaluate a pharmaceutical system s vulnerability to corruption and to determine which corrupt practices can have a major impact on the system s ultimate efficiency. We thus provide: (a) a systematic and quantifiable assessment of the extent to which a country s pharmaceutical system is vulnerable to corrupt practices; and (b) the identification of potential actions to increase the system s resistance to corruption, and ultimately, improve access of the population to good quality, essential medicines. The diagnostic framework and methodology permit users to identify key decision points in the pharmaceutical supply and distribution system (registration, selection, procurement, distribution, service delivery and use); assess the extent to which a country s current policies and practices at each of these key decision points make the system vulnerable to corruption; and understand the range of options that could reduce this vulnerability. This diagnostic tool has been designed for use by World Bank health specialists involved in health lending operations that include pharmaceutical components, and their national counterparts to help them identify points of vulnerability in the pharmaceutical system, address these points, and thus help ensure that pharmaceutical expenditures are maximized. While developed in the context of the health systems of Latin America and the Caribbean (and implemented in a pilot study in Costa Rica), the methodology can be modified with ease so that it is applicable to other regions.
-
Assessment of Governance and Corruption in the Pharmaceutical Sector : Lessons Learned from Low and Middle Income CountriesDiack, Aissatou; Dweik, Imad Subhi; Hawkins, Loraine; Seiter, Andreas (World Bank, Washington, DC, 2013-05-29)Pharmaceuticals are a critical input for the health sector. At the same time, the drug business sustains many individual and corporate livelihoods and produces handsome returns for those involved in the trade. Good governance is critical for the sector to maximize returns for public health and minimize risks for patients from ineffective or contaminated drugs. Given the large financial volume of the market, the potential for corruption is significant. Vulnerable points are those at which decisions about market access and purchasing are made. This includes institutional functions such as licensing, inclusion into formularies and public procurement as well as the individual prescriber, who selects drugs for a specific patient. Given the political and institutional resistance against more transparency from the beneficiaries of the status quo, assessment of governance and corruption in the sector is not a straightforward exercise. The authors developed a more indirect approach that relies on a broader assessment of the functioning of the sector and detection of patterns that suggest governance or management problems. From a developmental perspective, the focus is on reducing the impact of bad governance (high drug prices, stock-outs, bad quality of drugs in circulation, irrational use of drugs) rather than identifying the actors and bringing them to justice. Even if the governance level cannot be touched due to political resistance, it may be possible to address the problem from a technical or management angle. For example, electronic procurement platforms and inventory management systems make manipulation more difficult and allow for a faster discovery of irregularities. The assessment framework was applied in eight countries, with adjustments based on client demand and political viability. In most cases, a follow-up after the assessment could be documented, showing that the data provided had relevance and impact in the national policy dialogue. Three of the eight countries signed up to a longer term program to increase transparency in the sector (medicines transparency alliance), others initiated specific projects to address issues that were presented as a result of the initial assessment. In summary, the authors work could demonstrate that it is possible to effectively address pharmaceutical governance issues in the context of a broader sector assessment an approach that may face less political resistance than an inquiry based on a "governance and corruption" labeled instrument.
-
Health Systems Analysis for Better Health System StrengtheningBitran, Ricardo; Berman, Peter (2013-05-28)Health system strengthening and reform
 are often necessary actions to achieve better outcomes. The
 World Bank's 2007 strategy for health, nutrition, and
 population emphasizes the importance of health system
 strengthening for results. This paper proposes 'health
 systems analysis' as a distinct methodology that should
 be developed and practiced in the design of policies and
 programs for health system strengthening. It identifies key
 elements of health systems analysis and situates them in a
 logical framework supported by a wide range of data and
 methods and a sizable global literature. Health systems
 analysis includes evidence on health system inputs,
 processes, and outputs and the analysis of how these combine
 to produce the outcomes. It considers politics, history, and
 institutional arrangements. Health systems analysis proposes
 causes of poor health system performance and suggests how
 reform policies and strengthening strategies can improve
 performance. It contributes to implementation and
 evaluation. Examples from Mexico, Ethiopia, and Turkey
 illustrate the positive contributions health systems
 analysis has made to development of successful health system
 strengthening policies. Health systems analysis should be an
 integral part of good practice in health system
 strengthening efforts, including planning, policy
 development, monitoring, and evaluation. Health systems
 analysis can be conceived in a coherent and logical fashion
 and can be practiced and improved.